Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Department of Pharmacy, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Int J Pharm. 2021 Dec 15;610:121239. doi: 10.1016/j.ijpharm.2021.121239. Epub 2021 Nov 3.
The present study aimed to investigate how cocrystal solution-state stability may affect the polymorphic drug formation and transition during dissolution. In this work, curcumin-resorcinol (CUR-RES), curcumin-hydroquinone (CUR-HYQ) and curcumin-phloroglucinol (CUR-PHL) cocrystals were employed for dissolution studies in three buffer systems to study the effects of solvent and cocrystal thermodynamic stability. The undissolved solids were collected at designed time points and characterized by powder X-ray diffraction, differential scanning calorimetry and scanning electron microscopy. In pH 1.2 buffer, three cocrystals generated > 94% of metastable CUR form III with trace amount of stable CUR form I, while the phase purity of CUR form III recrystallized from buffers containing ethanol (EtOH) were decreased dramatically. For the same cocrystal, the cocrystal form maintained longer in the pH 1.2 buffer when compared with buffers containing EtOH. The phase purity of recrystallized CUR form III in the metastable cocrystal systems followed a linear relationship against CUR solubility, while the thermodynamically stable cocrystal resulted in a non-linear relationship. Due to different intermolecular interactions analyzed by H NMR, the stable cocrystal required a higher supersaturation level to precipitate pure CUR form III, in comparison to two metastable cocrystals. Our study offers important insights into mitigating the risk of recrystallization of drug polymorphs during cocrystal dissolution and demonstrates the potential use of cocrystals for drug polymorph preparation, both of which are crucial to the pharmaceutical cocrystal development and reformulation of existing drugs.
本研究旨在探讨共晶溶液稳定性如何影响药物在溶解过程中的多晶型形成和转变。在这项工作中,使用姜黄素-间苯二酚(CUR-RES)、姜黄素-对苯二酚(CUR-HYQ)和姜黄素-邻苯三酚(CUR-PHL)共晶在三种缓冲体系中进行溶解研究,以研究溶剂和共晶热力学稳定性的影响。在设计的时间点收集未溶解的固体,并通过粉末 X 射线衍射、差示扫描量热法和扫描电子显微镜进行表征。在 pH 1.2 缓冲液中,三种共晶生成了>94%的亚稳定 CUR 形式 III,只有微量的稳定 CUR 形式 I,而从含有乙醇(EtOH)的缓冲液中重结晶的 CUR 形式 III 的相纯度显著降低。对于相同的共晶,与含有 EtOH 的缓冲液相比,其在 pH 1.2 缓冲液中的共晶形式保持时间更长。亚稳定共晶体系中重结晶的 CUR 形式 III 的相纯度与 CUR 溶解度呈线性关系,而热力学稳定的共晶则呈非线性关系。由于通过 H NMR 分析的不同分子间相互作用,与两种亚稳定共晶相比,稳定共晶需要更高的过饱和度才能沉淀出纯的 CUR 形式 III。我们的研究为在共晶溶解过程中减轻药物多晶型再结晶的风险提供了重要的见解,并展示了共晶在药物多晶型制备中的潜在用途,这对于药物共晶的开发和现有药物的改剂型都至关重要。